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Objectives: Medical device companies are under growing pressure to provide
health-economic evaluations of their products. Cost-effectiveness analyses are commonly
undertaken as a one-off exercise at the late stage of development of new technologies;
however, the benefits of an iterative use of economic evaluation during the development
process of new products have been acknowledged in the literature. Furthermore, the use
of Bayesian methods within health technology assessment has been shown to be of
particular value in the dynamic framework of technology appraisal when new information
becomes available in the life cycle of technologies.
Methods: In this study, we set out a methodology to adapt these methods for their
application to directly support investment decisions in a commercial setting from early
stages of the development of new medical devices.
Results and Conclusions: Starting with relatively simple analysis from the very early
development phase and proceeding to greater depth of analysis at later stages, a
Bayesian approach facilitates the incorporation of all available evidence and would help
companies to make better informed choices at each decision point.
Keywords: Iterative economic evaluation, Bayesian analysis, Medical devices
The rapidly increasing range and expense of new medical de-
vices has created a growing need to demonstrate that a new
product is superior to an existing one in terms of “value for
money.” Although, formally, demonstrating safety and per-
formance of a new device is sufficient to receive CE-marking
(European Conformity), companies are under rising pressure
to articulate the value of their products in terms of their incre-
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mental cost-effectiveness. However, as conducting health
economic evaluations is not a core activity of most medi-
cal device companies, especially not the smaller ones, such
an evaluation, if undertaken at all, is usually done as a one-off
exercise at the late stage of development of new technologies.
Nevertheless, the importance of beginning to estimate cost-
effectiveness at an early stage of technology development,
and to iterate this evaluation as the development progresses,
is increasingly acknowledged, and recent examples of this
are reported in the literature (see, e.g., 4;6;18).
The benefits of an iterative estimation of the cost-
effectiveness of new technologies have previously been
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described by Sculpher et al. (12), suggesting a four-stage eco-
nomic evaluation that starts with an early assessment of the
technology, and as the development and testing progresses,
further analysis is undertaken that allows more confidence
to be attached to the cost-effectiveness estimates. Warburton
(19) later proposed what she called “the economic evaluation
loop,” including three steps, where the first one is an initial
estimate of costs and benefits of each strategy; the second
step explores the potential impact of uncertainty to target fu-
ture primary research which will be conducted in step three.
This process is repeated until the conclusions are considered
to be consistent under all plausible assumptions.
More recently, the use of Bayesian methods in health
technology assessment (HTA) has been reviewed for the NHS
HTA program (14). Bayesian methods allow for existing ev-
idence, knowledge or beliefs about a parameter, formally
expressed as a probability distribution, to be updated by new
information as it becomes available from further studies,
making explicit and quantitative use of all information avail-
able at that point. The NHS-HTA report has emphasized the
use of a Bayesian framework for making predictions, syn-
thesizing evidence, designing trials, and evaluating the value
of further information in a mainly theoretical way. The value
and practicality of the implementation of Bayesian methods
within the dynamic framework of HTA has been illustrated
by Fenwick et al. (5), evaluating the cost-effectiveness of
different preoperative patient management strategies before
major elective surgery. As such, their example related to a
situation where the innovation is fully developed for use in
practice and updating of evidence involves the accumulation
of hard trial data
There might be, however, a more commercial applica-
tion of an iterative Bayesian approach for medical devices.
Given that these are often fast-changing technologies (i.e.,
the life cycle of a specific type or variation of a device
is often as short as 18–24 months, considerably less than
that of pharmaceuticals for example) and their development
is characterized by a constant flow of incremental product
improvements, making early and rapid assessments of their
likely cost-effectiveness is of particular importance. Not only
to help companies reduce their failure rates, but also to help
ensure that patients and other users of medical devices gain
access to the most beneficial technologies as fast as possi-
ble. The iterative Bayesian approach might support this in
three ways: (i) by allowing the estimation of potential cost-
effectiveness to be part of the investment decision process
and to avoid investing in a technology that could never be
cost-effective; (ii) by supporting companies to prioritize be-
tween several competing possibly cost-effective concepts or
prototypes; (iii) by identifying from early stages of devel-
opment those parameters that have the largest impact on the
likely cost-effectiveness of the product to direct scarce re-
search resources. Whether or not a company should fund
additional research to reduce uncertainty relating to the re-
imbursement decision can be informed by means of value
of information (VOI) analysis, but this needs to be adapted
to inform the value of that further information to the com-
pany, rather than the standard value to society of reducing
uncertainty.
The objective of this study is to show how this iterative
Bayesian approach can be used to inform early decisions
regarding medical devices in situations where both the avail-
ability of data as well as time to perform the analyses may be
relatively scarce (e.g., as compared to the study of Fenwick
et al.). Although limited data and scarce analytical resources
may impose constraints to the level of sophistication of the
analyses to be performed, the applicability of the underly-
ing theory stills holds and we suggest to start with relatively
simple health economic analysis from the very early stages,
gaining greater depth of analysis in later stages as more in-
formation becomes available.
APPLICATION OF A COMBINED
ITERATIVE AND BAYESIAN FRAMEWORK
TO THE MEDICAL DEVICE INDUSTRY
Medical device manufacturers generally start off the device
development process with a concept or prototype product
and then make a ‘business case’ for it, which includes costs
of development, resource requirements and justification for
the project. Because the route to commercialization of a de-
vice is complicated by regulatory and reimbursement ap-
proval requirements, most medical device companies operate
some form of staged decision-making development process
that is regularly reviewed and decisions are taken as to
whether and how to proceed. At each stage, the decisions
are based on a mix of objective and subjective information
regarding costs and potential future benefits of the device.
Whereas attempts are made to remain as objective as pos-
sible, much early decision making is based on beliefs, and
in the vast majority of cases no formal economic evaluation
takes place until the late phase in the development of the
technology.
The proposed methodology fits into such a gate-staged
decision process. In this study, a simplified three-stage pro-
cess is considered to assess the potential cost-effectiveness
of the new technology. We take a collective view to the
economic evaluation where costs are those incurred in the
healthcare system and benefits include all health effects on
the individual (8), as this is likely to be the perspective which
will inform the eventual reimbusment decision. In the early
phase, most of the analysis is based on elicited beliefs and
plausible assumptions about the effects and costs of the new
technology; in the mid-phase some evidence would be avail-
able that will update our prior beliefs from the early stage
and can be incorporated into a decision model; in the final
phase, all available evidence can be formally synthesized to
inform a decision that will not necessarily ignore previous
evidence.
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Early Stage
An early stage is usually characterized by limited availability
of clinical and economic data and, therefore challenges the
applicability of standard health economic methods to inform
the decisions at hand. At this stage, the company also typi-
cally faces having to choose between a possibly large number
of alternative directions to take forward the development of
a particular technology, that is, the application of a device
to different types of interventions, different clinical settings,
or different clinical indications. In the absence of data re-
garding the new technology, the analysis should be based
on the available evidence concerning the current technology
that the new device aims to substitute or will compete with,
and expert opinion and/or assumptions regarding the likely
impact on cost and effectiveness of the new device. Then, the
expected incremental effectiveness of the new technology
can be estimated at a given willingness to pay per effective-
ness unit. For example, using the effectiveness measure of
quality-adjusted life-years (QALYs), the established willing-
ness to pay per QALY lies between £20 and 30k in the UK
as proposed by NICE (8). This approach has been described
in the literature as the “effectiveness gap” (12) or “headroom
method” (3). When the company has worked out the potential
cost of the new technology, this can be compared with the
results of this headroom analysis that would place a bound
on the maximum reimbursable price.
An example of the latter is the exploration of the
likely cost-effectiveness of tissue engineered bladder sub-
stitute as an alternative to the use of bowel in substitution
cystoplasty after resection of cancer (3). In the absence
of QALY values data, an estimate of the disutility of cur-
rent practice was made by means of a survey of urolo-
gists. A median utility value of 0.95 after cystoplasty was
found versus an estimated utility of 1.0 after having a tis-
sue engineered bladder (which represents the most opti-
mistic scenario). Assuming a mean of 10 years of life ex-
pectancy among the group that present this condition, this
provides an estimate of the incremental QALY of: 10 years
∗ (1–0.95) = 0.5; which considering the £30,000 maxi-
mum potential threshold is translated into: £30,000 ∗ 0.5 =
£15,000. Moreover, considering the savings by avoiding
bowel surgery of £1,000, the headroom is suggested to be
£16,000 under the most favorable circumstances. This sort
of analysis would inform a company in an early stage of
development that the use of tissue engineered bladder (as
compared to cystoplasty after resection for cancer) would
not be a cost-effective drawn on scarce resources for the
healthcare system, and hence unlikely to be reimbursed, if
could not be produced in such a way that its eventual market
price is considerably less than £16,000.
The main limitations of this stage are the difficulties of
eliciting prior beliefs about the variables for which no evi-
dence yet exists. There is a growing body of research into
how to elicit expert’s knowledge accurately and reliably (9).
The elicitation methods can be made more or less formal, but
the use of plausible assumptions from expert opinion will fit
better in the time frame of this early assessment than more
sophisticated and time-consuming techniques. In the context
of medical devices, relatively good prior information on the
performance of the device may be available because their
physical mechanism makes their effectiveness generally ro-
bust to small changes. To this extent, data from earlier studies
on previous generations of the device, or studies from differ-
ent locations can provide relevant information (1). Although
this analysis can only be considered as indicative, it can still
provide some evidence to prioritize medical devices to avoid
investing in devices which could never be cost effective.
Mid Stage
At a mid-stage, typically, observational studies would pro-
vide some clinical evidence of the effectiveness of the new
technology, and some initial cost estimates would be avail-
able. Under these conditions, decision-analytic modeling
techniques can be applied and the Bayesian approach would
provide a means of combining the new, but limited, data
with the beliefs previously identified. The prior beliefs about
the new technology, ideally elicited from a group of experts,
would be used as the prior distribution of the variable of
interest, which can now be updated with the evidence that
has become available in this stage. In this way, the Bayesian
approach still allows for the expert opinion based on ex-
tensive experience to influence the estimated outcome. This
is of particular interest when the newly available evidence
comes from uncontrolled and small trials that may report
extreme values that should not be taken at face value (15).
Also, very critical at this stage is the need to know what
extra information would be most valuable for the company.
Simple sensitivity analyses can help to identify which are
the key parameters affecting the cost-effectiveness of their
product. These analyses are relatively easy to undertake and
to understand, and will help the company to find out whether
a change in these parameters is likely to make a meaning-
ful difference to the model outcomes and potentially decision
making as based upon this. However, the cost in terms of time
and resources of collecting this extra information is typically
high, and companies will face the decision of whether or not
they should fund additional research to reduce uncertainty.
Value of information analysis could provide insights into the
value of carrying out further research, and highlight the vari-
ables in the model for which additional information would be
most valuable, if formal analysis were to be undertaken from
a societal perspective. This part of the Bayesian approach
is based on the idea that information is valuable because
it reduces the expected costs of uncertainty surrounding a
decision. The expected costs of uncertainty are determined
by the probability that a decision, based on existing (prior)
information, will be wrong and by the consequences of that
potentially wrong decision to the society (2). The expected
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value of perfect information thus reflects the discrepancy
between the current information position and a position
of perfect information (no uncertainty). When this analy-
sis is taken one step further to estimate the so called “par-
tial value of information,” it informs us for which specific
consequences of the technology (e.g., impact on utilities,
costs, or health status) more information is needed to make
a less uncertain decision in the future. However, as stan-
dard VOI is based on the value to society, and not on the
value to a company of further information, its relevance in a
commercial context is less clear. Ideally in this context, the
methodology of VOI analysis would be adapted to inform
the value to a company of conducting further research. The
probability of making the wrong decision, in this case to
abandon (proceed with) the device when the eventual pur-
chase decision is (not) to reimburse the product, has a po-
tential cost to a company that should be compared with the
cost of collecting further information internally to reduce
uncertainty.
Identifying the magnitude of the uncertainty and the pa-
rameters with the biggest impact on it is a very important
contribution at this stage when there is still scope for fur-
ther research before a final commercial “go ahead” decision
needs to be made. An example of cost-effectiveness assess-
ment at this stage, albeit to make a decision as to whether a
publicly funded trial was justified, is given by Girling et al.
(6). They focus on an early assessment of second generation
left ventricular assist devices (LVAD) as compared to optimal
medical care for patients with heart failure but not eligible
for heart transplantation. Using data from a randomized con-
trolled trial (RCT) of first generation LVADs, and prior distri-
butions elicited from a group of leading clinicians regarding
the effect of second generation LVADs, they concluded that
the technology is extremely unlikely to be cost-effective if
the device costs as much as £60,000. They also undertook
a Bayesian VOI analysis to assess the value of discovering
the actual size of the survival benefit of the device (a key
parameter in the model). The prediction was that the public
cost of a future LVAD trial would not be justified over any
reasonable period unless the expectation was that the cost of
the device would in future be substantially less than £60,000.
Given the increasing complexity of the techniques, this
mid-stage becomes more demanding in terms of data inputs,
for which robust evidence may or may not yet be available. A
substantial effort may be required to elicit and apply plausi-
ble assumptions and distributions to parameters for which no
evidence is yet available. The approach also requires some
experience with building decision-analytic models. Never-
theless, such models provide an ideal framework to update
the results when new evidence becomes available. This stage
can if needed be refined at several points of time and it en-
ables aggregating evidence from a wide range of sources. In
each stage, the “posterior” estimate of a parameter value that
emerges from a refinement becomes the “prior” estimate that
goes into the next stage of refinement.
Late Stage
The health economic analyses undertaken in the late stage are
typically designed to inform external decision makers (e.g.,
health service payers) about the expected cost-effectiveness
of the new technology, and so to make the case for reim-
bursement of the product. A reimbursement decision would
preferably be based on a model regarding incremental effec-
tiveness and costs underpinned by evidence provided by large
RCTs rather than by speculative evidence (11). Ideally, early
assessment would have identified the parameters that have
a relatively large impact on the product’s cost-effectiveness
and for which additional and better information is thus most
valuable. This would subsequently be incorporated into the
RCT design so that it provides the key data in the most suit-
able way, for example in terms of sample size and length of
follow-up and so makes most efficient use of research re-
sources. As previously noted, Bayesian methods provide the
possibility of accumulating the previously collected evidence
with the new data. However, because prior beliefs and ob-
servational data may well be affected by bias, the techniques
that are used to combine randomized and observational ev-
idence should take into account the different nature of data
sources. Meta-analyses that simply pool data from all sources
together are not likely to be appropriate because they fail to
recognize the different types of evidence being synthesized.
Several methods can be used to overcome this problem, and
those vary by the sophistication of the technique. The most
straightforward approach is to use observational data as the
prior distribution for the information provided by the RCT. If
we have assessed the observational data to be of sufficiently
high quality, the result of a meta-analysis that combines these
data can form the prior distributions. Otherwise, the obser-
vational evidence can be down-weighted using methods that
introduce some caution around the potentially biased esti-
mates (for instance, the priors could be centered around the
observational pooled estimate but a much larger variance
can be used). This methodology was explored for the assess-
ment of the efficacy of electronic fetal heart rate monitoring
(EFM) (16). The authors compared results of meta-analyses
that include and exclude the observational data in addition
to the randomized studies, and illustrated different ways of
combining the different types of evidence. The inclusion of
observational data in general favored EFM. More sophisti-
cated methods involve the use of a hierarchical model to pool
data from different sources simultaneously. Those methods
accommodate qualitative and quantitative heterogeneity in
terms of the size of the effect of a technology, and study de-
sign of the evidence. Prevost, Abrams, and Jones (10) applied
a three level (i.e. study level; study type level; and population
level) Bayesian model to estimate the relative risk of breast
cancer mortality in studies of breast cancer screening, and
combined evidence from both randomized and nonrandom-
ized trials. They found that this sophisticated approach gave
an almost identical estimate to that obtained by performing a
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meta-analysis ignoring study type, but the three level model
allowed for greater uncertainty and hence produced a wider
95 percent confidence interval.
RCTs are considered to be the most powerful research
design for establishing whether an intervention is effective,
because they most successfully eliminate bias as compared
to other research design (17). Different types of studies have
been hierarchically ordered as regards their methodologi-
cal quality as level 1 (RCTs), level 2 (controlled observa-
tional studies), level 3 (observational studies without control
groups), and level 4 (expert opinion). It has been argued that
the elicited views of informed experts, or the observational
evidence collected in previous stages, become irrelevant in
the presence of large RCTs. Especially as the empirical evi-
dence has accumulated, the need for subjective opinion dis-
appears, and the estimates are dominated by the evidence
provided by the data. Others however, have recognized that
although studies lower in the hierarchy are more prone to bias,
RCT data are often limited to selected populations, short time
spans and selected comparator treatments, and thus, the value
of evidence from anywhere in the hierarchy will depend on
its quality and relevance (8). Moreover, RCTs are usually
designed to detect specific outcomes but they may not be
powered to measure other outcomes of interest, such as a
low probability for a severe adverse event. Therefore, prior
information based on vast expert knowledge or observational
evidence can enhance the evidence from RCTs, and Bayesian
modeling does provide ways of combining the evidence from
this variety of disparate sources.
DISCUSSION
In this study, we have set out a methodology for integrating
health economic modeling in early, mid and late development
stages of medical devices, and for updating this analysis in
an iterative process using a Bayesian approach.
Whereas others have previously demonstrated the appli-
cability of this approach for supporting reimbursement deci-
sions for innovations (i.e., mainly pharmaceuticals) for which
relatively hard data may be available, and the resources and
time available to perform the analyses is generally longer, we
sought to adapt these methods as to reliably support medical
device development cycles without unduly delaying these.
The immediate advantage of an early analysis of the po-
tential cost-effectiveness of a new technology is to form a
basis for prioritizing between several potential device devel-
opments in the face of scarce developmental resources. By
focusing on those devices most likely to be cost-effective, the
failure rate at each stage of the development process should
be reduced, as should be the development costs. If further
investment on research is driven by identifying the parame-
ters for which more information is most valuable, this is also
likely to enhance efficient use of research and development
resources. For users of medical devices, this might translate
in earlier access to the most beneficial new technologies.
Notwithstanding its likely appeal, there are a couple of
potential caveats to the described approach that need con-
sideration. First, because many of the techniques described
in this study are not simple and need a substantial level
of expertise on economic evaluation and evidence synthe-
sis methods, the cost and time involved in developing these
analyses may act as a barrier to their integration into the
development cycle of a new product. We aimed to address
this issue by varying the sophistication of the models from
stage to stage, allowing for simple health economic models
at the start, and proceed to greater depth of analysis at the
later stages. The critical element remains that at any given
stage, decisions are taken based on analyses that contain the
best knowledge that is available about the product but are
also feasible within the data and time restrictions. Second, it
has to be acknowledged that there might be limitations to the
extent to which meaningful interpretations can be derived
from early stage evaluation due to both the learning curve
phenomenon and the fact that the process of innovation in
medical devices is one of continuous incremental improve-
ments in close interaction with the users of the technology
(13). Both factors might be difficult to estimate at this point in
the development, even more so when the intended users are
not involved. Interaction between all stakeholders as early
as possible in the development cycle is therefore strongly
recommended (7). Finally, the focus in this study has been
on developing a methodology for assessing the economic
value of technologies to inform reimbursement decisions,
which are taken from a societal or a health system perspec-
tive. Although adopting such a wider perspective from the
early start is likely to be the best approach for anticipating
the reimbursement decision, in addition there should be a
more commercial perspective that can inform a firm’s invest-
ment decision. The models could inform an early prediction
of firm’s potential revenues and the optimum price based
on the estimated likely cost-effectiveness in daily practice.
The commercial analysis would thus build on the features of
the cost-effectiveness analysis, but would require additional
information on production cost, scale, and so on. Further re-
search, however, is needed to investigate the practicality and
likely value of the approach outline in this study to med-
ical device companies and the wider healthcare society, as
well as to explore a methodology that appropriately address
the value of information analysis applied to a commercial
perspective.
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